BioMarin Pharmaceutical Inc (BMRN.xnas) is a world-leading biotechnology company headquartered in California, America. BioMarin operates in the United States, South America, Asia, and Europe with 34 offices locations in 20 countries and they will continue to expand into new markets and grow their team. BioMarin develops and commercialises first in class therapies for rare genetic diseases and it is a pioneer in treatments for debilitating and life-threatening conditions with business and research in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I) and the first to provide therapeutics for phenylketonuria (PKU). The company employes 3,000 people and has $1.7B (USD) in 2019 yearly revenue. BioMarin Pharmaceutical Inc stock (BMRN.xnas) is listed on NASDAQ and had a market capitalisation of $15.47B (USD) as of December 2021. The biotech sector has been in focus as of November 2021 due to the COVID-19 pandemic with drug approvals, with BioMarin being approved for Voxzogo injection. BioMarin plans to use the ongoing open-label extension studies to fulfil the post-marketing requirements of continued approval.
BioMarin Pharmaceutical Inc (BMRN)
Stay updated with BioMarin Pharmaceutical Inc (BMRN) share price and insights to enhance your investment strategies. Stay informed with FP Markets South Korea.